AnaptysBio - Overview
About
Overview
Strategy
Management
Board of Directors
Research and Development Committee
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Imsidolimab
Rosnilimab
ANB032
Partnerships
Investors / News
Overview
News
Events
Goverance
Stock Information
Analyst Coverage
SEC Filings
FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Toggle
Overview
Imsidolimab
Rosnilimab
ANB032
Partnerships
Pipeline
Imsidolimab (ANB019):
Anti-IL-36R
DEVELOPMENT STAGE & ANTICIPATED MILESTONES
THERAPEUTIC
INDICATION
COMMERCIAL
RIGHTS
ANTIBODY
PROGRAM
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Phase 1 Data
Presented at
EAACI 2018
GALLOP: Phase 2 Data Presented At
EADV Congress on October 2nd 2021
Phase 3 Initiated
Q3 2021
ACORN: Topline Data Anticipated H1 2022
HARP: Topline Data Anticipated H2 2022
Generalized Pustular
Psoriasis
Acne Vulgaris
JEMPERLI (dostarlimab):
Anti-PD-1 Antagonist
FIRST: Ongoing
US BLA and EU MAA
Approved April 2021
US BLA Approved
August 2021
OPAL: Ongoing
dMMR Pan-Tumor
Ovarian Cancer
dMMR Endometrial Cancer
PERLA: Ongoing
NSCLC
Cobolimab (GSK4069889):
Anti-TIM-3 Antagonist
COSTAR: Dostarlimab Combination Trial Ongoing
GSK4074386:
Anti-LAG-3 Antagonist
CITRINO: Dostarlimab Combination Trial Ongoing
Immuno-Oncology
TSR-075: Anti-PD-1/
LAG-3 Bispecific
IND-Enabling
Studies Ongoing
Immuno-Oncology
CC-90006:
Anti-PD-1 Agonist
Ongoing
Psoriasis
Undisclosed
Ongoing
Inflammation
ANB032: Anti-BTLA Modulator
Inflammatory Diseases
NSCLC
Hidradenitis
Suppurativa
Topline Phase 1
Data Anticipated
H1 2022
Rosnilimab (ANB030):
Anti-PD-1 Agonist
Alopecia Areata
Phase 1 Top-Line
Data Anticipated
Q4 2021
Phase 2 Initiation Anticipated in Q4 2021